• LivaNova disclosed new OSPREY substudy data at SLEEP 2026 on PolySync programming for its aura6000 implant therapy in obstructive sleep apnea.
• Personalized reprogramming converted many prior non-responders into responders, lifting the overall response rate to 84.5%.
• The approach was reported as well tolerated, with no serious treatment-emergent adverse events in the substudy.
• PolySync is slated for inclusion in the commercial pHGNS product, supporting earlier patient-specific titration to broaden uptake.
• LivaNova also flagged a next-generation OSA device, targeting an FDA PMA supplement filing in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202606161057BIZWIRE_USPR_____20260615_BW597427) on June 16, 2026, and is solely responsible for the information contained therein.